Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MindBio Therapeutics Corp C.MBIO

MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. It develops a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder. The underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.


CSE:MBIO - Post by User

Post by Smokey1958on May 02, 2024 10:44am
88 Views
Post# 36019457

Where does the money come from?

Where does the money come from?MBIO has to have significant research connections to move forward as quickly as they have been in branching out from Phase 1 to Phase 2 trials and already forecasting Phase 3 trials. The researchers dont only wait for money from public individual or institutional investors. As an example here is the research grant (government) awarded to Dr. Rachael Sumner two months ago that has no doubt led in part to the recent NRs. Congratulations to Dr Rachael Sumner who recently received an AMRF Postdoctoral Fellowship. She will receive $264,233 over the next 2 years for her on the work on the myriad of neurological and psychiatric disorders caused by, or made worse by, major changes in hormones around the menstrual cycle, pregnancy, and menopause.
<< Previous
Bullboard Posts
Next >>